News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
643,619 Results
Type
Article (37844)
Company Profile (115)
Press Release (605651)
Multimedia
Podcasts (71)
Webinars (11)
Section
Business (172725)
Career Advice (2769)
Deals (32417)
Drug Delivery (100)
Drug Development (72714)
Employer Resources (159)
FDA (15759)
Job Trends (14603)
News (300545)
Policy (29032)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2677)
Academic (1)
Accelerated approval (29)
Adcomms (28)
Allergies (144)
Alliances (43318)
ALS (174)
Alzheimer's disease (1702)
Antibody-drug conjugate (ADC) (295)
Approvals (16060)
Artificial intelligence (519)
Autoimmune disease (158)
Automation (35)
Bankruptcy (289)
Best Places to Work (12089)
BIOSECURE Act (18)
Biosimilars (182)
Biotechnology (80)
Bladder cancer (158)
Brain cancer (56)
Breast cancer (640)
Cancer (4786)
Cardiovascular disease (392)
Career advice (2316)
Career pathing (38)
CAR-T (284)
CDC (40)
Celiac Disease (2)
Cell therapy (758)
Cervical cancer (35)
Clinical research (62796)
Collaboration (1730)
Company closure (3)
Compensation (1164)
Complete response letters (52)
COVID-19 (2580)
CRISPR (92)
C-suite (864)
Cystic fibrosis (150)
Data (6300)
Decentralized trials (1)
Denatured (16)
Depression (131)
Diabetes (487)
Diagnostics (6927)
Digital health (45)
Diversity (7)
Diversity, equity & inclusion (39)
Drug discovery (247)
Drug pricing (159)
Drug shortages (21)
Duchenne muscular dystrophy (216)
Earnings (71813)
Editorial (58)
Employer branding (21)
Employer resources (144)
Events (107585)
Executive appointments (1015)
FDA (18912)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1473)
Gene editing (196)
Generative AI (41)
Gene therapy (588)
GLP-1 (849)
Government (4245)
Grass and pollen (7)
Guidances (381)
Healthcare (19887)
HIV (55)
Huntington's disease (43)
IgA nephropathy (79)
Immunology and inflammation (227)
Immuno-oncology (53)
Indications (105)
Infectious disease (2840)
Inflammatory bowel disease (194)
Inflation Reduction Act (12)
Influenza (111)
Intellectual property (250)
Interviews (546)
IPO (16302)
IRA (39)
Job creations (2872)
Job search strategy (1896)
JPM (52)
Kidney cancer (17)
Labor market (67)
Layoffs (498)
Leadership (37)
Legal (6400)
Liver cancer (83)
Longevity (14)
Lung cancer (629)
Lymphoma (368)
Machine learning (43)
Management (60)
Manufacturing (762)
MASH (164)
Medical device (14397)
Medtech (14452)
Mergers & acquisitions (17289)
Metabolic disorders (1169)
Multiple sclerosis (158)
NASH (13)
Neurodegenerative disease (321)
Neuropsychiatric disorders (84)
Neuroscience (2938)
NextGen: Class of 2026 (6714)
Non-profit (4857)
Now hiring (53)
Obesity (503)
Opinion (280)
Ovarian cancer (167)
Pain (211)
Pancreatic cancer (224)
Parkinson's disease (295)
Partnered (32)
Patents (488)
Patient recruitment (494)
Peanut (58)
People (53239)
Pharmaceutical (29)
Pharmacy benefit managers (27)
Phase 1 (19605)
Phase 2 (27838)
Phase 3 (20752)
Pipeline (5187)
Policy (251)
Postmarket research (2018)
Preclinical (8031)
Press Release (62)
Prostate cancer (236)
Psychedelics (45)
Radiopharmaceuticals (288)
Rare diseases (845)
Real estate (4938)
Recruiting (68)
Regulatory (22685)
Reports (31)
Research institute (2506)
Resumes & cover letters (451)
Rett syndrome (27)
RNA editing (14)
RSV (76)
Schizophrenia (147)
Series A (237)
Series B (191)
Service/supplier (6)
Sickle cell disease (102)
Special edition (17)
Spinal muscular atrophy (156)
Sponsored (33)
Startups (3059)
State (2)
Stomach cancer (9)
Supply chain (98)
Tariffs (73)
The Weekly (54)
Vaccines (920)
Venture capital (78)
Weight loss (307)
Women's health (75)
Worklife (20)
Date
Today (113)
Last 7 days (642)
Last 30 days (2166)
Last 365 days (30870)
2026 (3082)
2025 (31187)
2024 (35943)
2023 (41285)
2022 (52113)
2021 (57039)
2020 (55564)
2019 (48730)
2018 (36627)
2017 (32100)
2016 (30369)
2015 (35473)
2014 (24629)
2013 (19205)
2012 (20727)
2011 (21532)
2010 (18623)
Location
Africa (777)
Alabama (89)
Alaska (7)
Arizona (233)
Arkansas (12)
Asia (37568)
Australia (6670)
California (11392)
Canada (3294)
China (1115)
Colorado (482)
Connecticut (489)
Delaware (335)
Europe (87248)
Florida (1691)
Georgia (371)
Hawaii (3)
Idaho (61)
Illinois (878)
India (64)
Indiana (529)
Iowa (21)
Japan (424)
Kansas (124)
Kentucky (41)
Louisiana (26)
Maine (83)
Maryland (1380)
Massachusetts (8367)
Michigan (343)
Minnesota (639)
Mississippi (5)
Missouri (137)
Montana (34)
Nebraska (27)
Nevada (126)
New Hampshire (84)
New Jersey (3064)
New Mexico (31)
New York (3010)
North Carolina (1522)
North Dakota (10)
Northern California (5569)
Ohio (344)
Oklahoma (22)
Oregon (42)
Pennsylvania (2295)
Puerto Rico (23)
Rhode Island (46)
South America (1093)
South Carolina (66)
South Dakota (1)
Southern California (4472)
Tennessee (173)
Texas (1775)
United States (40768)
Utah (350)
Vermont (1)
Virginia (272)
Washington D.C. (76)
Washington State (946)
West Virginia (3)
Wisconsin (120)
Wyoming (2)
643,619 Results for "medivir ab".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Number of shares and votes in Medivir AB on 28 June 2024
Medivir AB announces that the number of shares and votes in Medivir has changed during June 2024 as a result of the issue of 1,700,000 shares of series C and the reclassification of 114 587 shares of series C to ordinary shares which was carried out as a part of the implementation of the incentive program resolved by the general meeting on 7 May 2024.
June 28, 2024
·
2 min read
Number of shares and votes in Medivir AB on 31 January 2024
Medivir AB announces that the number of shares and votes in Medivir has changed during January 2024 as a result of the rights issue resolved on by Medivir on 7 November 2023 and the directed issue to Hallberg Management AB resolved on by Medivir on 22 January 2024.
January 31, 2024
·
2 min read
Press Releases
Change in Number of Shares and Votes in Alligator Bioscience AB
February 1, 2026
·
1 min read
Press Releases
EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB
February 5, 2026
·
2 min read
Medivir to present at Redeye Growth Day
Medivir AB announces that the company will participate at Redeye Growth Day, today May 30, 2024.
May 30, 2024
·
1 min read
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
Medivir AB announced that Medivir’s licensee, Tango Therapeutics, has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts.
May 23, 2024
·
2 min read
Business
Medivir 2023 Annual Report published
Medivir AB announces that the Annual Report for 2023 now is available at the company’s website.
April 4, 2024
·
2 min read
Notice of Extraordinary General Meeting in Medivir AB (publ)
The shareholders in Medivir AB reg. no. 556238-4361 are hereby convened to the extraordinary general meeting, which will be held on Friday 1 December 2023, at 10.00 CET at Helio GT30, Grev Turegatan 30, Stockholm, Sweden.
November 7, 2023
·
9 min read
Medivir to present at Investing in Oncology Forum on April 10
Medivir AB announces that the company will participate at the Investing in Oncology Forum on April 10, 2024.
April 9, 2024
·
1 min read
Press Releases
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
January 8, 2026
·
11 min read
1 of 64,362
Next
